# Statin Contrast Induced Nephropathy Prevention

Study · id `cardio:ct-nct01185938` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01185938](<https://clinicaltrials.gov/study/NCT01185938>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01185938

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

## Technical summary

Registry record NCT01185938. Randomized; no masking; primary purpose prevention. Start 2010-07 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 500 participants (enrolled count; ClinicalTrials.gov record NCT01185938, source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01185938, source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01185938, source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)
- Completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01185938, source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT01185938, source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01185938-2012-10-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Statin Contrast Induced Nephropathy Prevention
- Acronym: PRATO-ACS
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Rosuvastatin
- Lead sponsor: Centro Cardiopatici Toscani
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) (`cardio:pubmed-24076283`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study (`cardio:pubmed-25440809`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention) (`cardio:pubmed-25523533`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c6556aebebf9c20cba3deda23427be62ca60f9ab118bb10624d6d392d1e6bae1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
